1. INTRODUCTION

If you spend enough time in the boardrooms of Antibody-Drug Conjugate (ADC) innovators, you eventually witness a peculiar phenomenon. You see a company with a brilliant clinical asset, robust funding, and secured capacity at top-tier CDMOs, yet they remain perpetually stalled. The Gantt chart says they should be in Phase II; the reality is they are fighting fires in tech transfer, bleeding cash while waiting for a manufacturing slot that vanished three months ago.

The prevailing narrative in the market is that these delays are scientific. We tell investors that “process complexity” or “unforeseen characterisation hurdles” are to blame. We point to the inherent difficulty of handling high-potency warheads or the stochastic nature of conjugation. But as someone who has spent years assessing the operational architecture of these companies – both from inside executive hiring mandates and through direct platform diligence work – I can tell you that science is rarely the root cause.

The failure mode is almost always organizational interface failure.

Unlike standard monoclonal antibodies (mAbs) or small molecules, which follow a linear manufacturing pipeline, ADCs operate on a fractured, multi-disciplinary supply chain. It is a dependency chain that requires the seamless integration of two fundamentally opposing scientific philosophies—biologics and synthetic chemistry – into a single, sterile drug product.

When we analyse the collapse of ADC timelines, we rarely find that the chemistry failed or the cell line died. We find that the people managing the handoffs didn’t understand the constraints of the adjacent layer. We find a VP of CMC who grew up in small molecules making assumptions about protein stability that destroy yield. We find a Quality Head from the biologics world stalling a batch release because they are applying large-molecule logic to a linker-payload impurity profile.

The industry treats “CMC leadership” as a generic commodity. The assumption is that if you have run a plant, you can run an ADC program. This is consistently where capital erosion begins. A leader who is a genius at fermentation may be a liability in high-potency containment. A master of sterile fill-finish may suffocate the process development required for conjugation.

This article maps the reality of the ADC ecosystem. We will dissect the “Y-Shaped” execution stack, not as a theoretical manufacturing flow, but as a human capital challenge. We will answer the critical question facing CEOs and Technical Ops leaders: Where does talent realistically transfer between these layers, and where does it hit a wall?

---

2. THE ADC Y-SHAPED EXECUTION STACK

To understand talent mobility, one must first respect the physical reality of the asset. The industry often defaults to “pipeline” thinking – a left-to-right flow where materials move sequentially through development stages. This is accurate for a monoclonal antibody or a standard small molecule. It is fatal for an ADC.

In practice, ADC manufacturing functions as a Y-shaped dependency chain.

The Parallel Arms (Layer 1 & Layer 2)

At the top of the “Y,” two distinct supply chains operate in parallel, often on different continents, and almost always in radically different facility types.

• Layer 1 (The Antibody Backbone): This is the world of living organisms. It is upstream cell culture, bioreactors, and downstream protein purification. It is governed by biological variability. The timeline is dictated by the growth rate of CHO (Chinese Hamster Ovary) cells. It is aqueous, ambient, and relies on filtration and chromatography.
• Layer 2 (Linker & Payload Chemistry): This is the world of synthetic organic chemistry. It involves high-potency active pharmaceutical ingredients (HPAPIs), complex multi-step synthesis, and solvent-based processing. It is governed by stoichiometry and chemical precision. The timeline is dictated by reaction kinetics and crystallization rates. It is toxic, often explosive, and relies on reactors and dryers.

These two layers operate in isolation. Yet, their timelines must synchronise perfectly. If the antibody batch (Layer 1) is delayed by a contamination event, the linker-payload (Layer 2) sits in storage. However, complex linkers often have limited stability; they degrade. By the time the antibody is ready, the payload may be out of spec. Conversely, if the payload synthesis yields a new impurity profile, the antibody sits frozen, burning shelf-life and incurring massive carrying costs.

The Convergence Node (Layer 3)

The arms of the “Y” crash together at Layer 3: Bioconjugation. This is the integration node. It is where a fragile biological protein is subjected to chemical modification. It is the single highest point of failure in the stack because it requires the reconciliation of two opposing sets of material properties.

Here, you are asking a protein – which evolves to exist in water at 37°C – to survive exposure to organic solvents and reactive chemicals. You are asking a chemical reaction to proceed with precision on a substrate (the antibody) that varies slightly with every batch.

The Downstream Stream (Layers 4 & 5)

Once conjugation is successful, the process flows linearly downward, but the constraints tighten.

• Layer 4 (Fill & Finish): The formulated Bulk Drug Substance (BDS) is processed into sterile Drug Product (DP). Because ADCs are cytotoxic, they cannot be filled on standard lines. They require specialized containment lines, which are the scarcest resource in the global CDMO network.
• Layer 5 (Characterisation & QC): The analytical gatekeeper. This layer validates the safety, potency, and identity of the final molecule. It must answer questions that standard biologics never face, such as “What is the distribution of drug molecules per antibody?” and “How much free toxin is loose in the vial?”

The structural fragility of this Y-shape dictates the talent requirement. A leader who excels in the linear flow of Layer 4 may be utterly paralyzed by the parallel complexity of Layers 1 and 2. Conversely, a genius in the chemistry of Layer 2 may destroy the economics of the program by failing to anticipate the sterile requirements of Layer 4.

---

3. DETAILED ROLE MAPPING BY LAYER

To assess transferability, we must define what “experience” actually means in each layer. It is not enough to look for “Senior Director of Manufacturing” on a CV. We must look at the specific functional domains, the “muscle memory” developed in those roles, and the blind spots inherent to each layer.

LAYER 1: ANTIBODY BACKBONE (Biologics)

• Core Domains: Cell Line Development (CLD), Upstream Process (USP), Downstream Process (DSP), Viral Inactivation.
• Key Roles: Director of Upstream Processing, Head of DSP Tech Transfer, VP of Biologics Manufacturing.
• The Daily Reality: These leaders manage living systems. Their intuition is built around cell viability, titer, and glycosylation profiles. They are used to huge stainless steel or single-use bioreactors. They think in terms of “harvest” and “purification.” They are comfortable with the idea that the process is the product – meaning if you change the stir speed, you change the molecule.
• Skill Assumptions: They assume variation is inevitable and must be controlled within a “design space.” They are experts in chromatography and ultrafiltration/diafiltration (UF/DF). They prioritize bio-burden control (keeping bacteria out) above almost all else.
• The Blind Spot: They often lack deep appreciation for small molecule degradation pathways or solvent compatibility. They fear contamination, but they often lack the “containment” mindset required for toxins. They treat safety as “biosafety” (protecting the environment from the bug), not “chemical safety” (protecting the operator from the drug).

LAYER 2: LINKER & PAYLOAD CHEMISTRY (HPAPI)

• Core Domains: Synthetic Chemistry, Flow Chemistry, Crystallization, Solid State Characterisation, Containment Engineering.
• Key Roles: Director of Chemical Development, Head of API Supply Chain, Senior Director of Process Chemistry.
• The Daily Reality: These leaders manage dangerous, highly reactive powders. Their world is defined by OEL (Occupational Exposure Limit) bands – operating in isolators where a microgram of dust is a safety breach. They think in terms of reaction kinetics, solvent ratios, and crystallization polymorphs. They are used to “forcing” reactions with heat and pressure.
• Skill Assumptions: They assume the process is deterministic – if you mix A and B correctly, you get C. They focus on chemical purity (99.9%) rather than biological activity.
• The Blind Spot: They treat the “backbone” (the antibody) as just another reagent, often failing to respect its shear sensitivity or temperature instability. They struggle with the concept of “heterogeneity” – to a chemist, a mixture of species is a failed reaction; to a biologist, it’s a standard antibody batch.

LAYER 3: BIOCONJUGATION (Integration)

• Core Domains: Reaction Engineering, TFF (Tangential Flow Filtration), Formulation, Purification (post-conjugation).
• Key Roles: Head of Conjugation MSAT (Manufacturing Science & Technology), Director of ADC Process Development.
• The Daily Reality: This is the bridge. Leaders here must manage the reaction of the payload to the antibody without denaturing the antibody or hydrolyzing the linker. They manage the Drug-to-Antibody Ratio (DAR). They are constantly balancing the need to drive the reaction to completion (Chemistry mindset) with the need to be gentle with the protein (Biology mindset).
• Skill Assumptions: They must speak both “Bio” and “Chem.” They are masters of TFF and managing aggregation. They understand that the “process” is a compromise.
• The Blind Spot: They are often squeezed from both sides—blamed by Layer 1 for “ruining the protein” and by Layer 2 for “wasting the payload.” They can become too focused on the “step” and lose sight of the “supply chain” feeding them.

LAYER 4: FILL & FINISH (Sterile DP)

• Core Domains: Aseptic Processing, Lyophilization (Freeze Drying), Visual Inspection, Sterility Assurance.
• Key Roles: Site Head of Sterile Operations, Director of Fill/Finish MSAT, VP of Drug Product.
• The Daily Reality: This is a mechanical and microbiological discipline. It is about scheduling, line speed, vial integrity, and absolute sterility. The toxicity of ADCs adds a layer of containment complexity (toxic sterile lines), but the core task is filling vials. It is a zero-tolerance environment.
• Skill Assumptions: They assume the material arriving is homogenous and stable. Their focus is on the container and the environment, not the molecule’s synthesis. They are risk-averse operationalists.
• The Blind Spot: They have little visibility into the upstream chaos. If the bulk drug substance arrives late or with slight turbidity, their schedule collapses. They lack the scientific depth to “fix” a batch; they can only reject it.

LAYER 5: CHARACTERISATION & QC (Analytics)

• Core Domains: Method Development/Validation, Stability Studies, Potency Assays, Release Testing.
• Key Roles: Senior Director of Analytical Development, Head of Quality Control (QC), VP of Quality.
• The Daily Reality: This is the data layer. ADC analytics are exponentially more complex than mAbs because of the heterogeneity of the mixture (different DAR species, free payload, etc.). They are the adjudicators of truth.
• Skill Assumptions: They act as the “supreme court” of the process. They deal in chromatograms, mass spectrometry, and binding assays. They value precision and reproducibility above speed.
• The Blind Spot: They can become disconnected from manufacturing reality, setting specifications that are analytically perfect but operationally unachievable. They may not understand the cost or time implications of the tests they design.

---

4. THE ADC TALENT MOBILITY MATRIX

When advising boards on hiring, I utilise a Mobility Matrix to assess risk. The principle is simple: Talent transfer success is inversely proportional to the “conceptual distance” between layers.

1. Same-Layer Transitions (Safe): Moving a VP from a mAb plant to an ADC Layer 1 role is seamless. The physics are identical. The only new variable is that the output of their plant is an intermediate, not a final product.
2. Adjacent-Layer Transitions (Conditional): Moving a Purification leader from Layer 1 to Layer 3 (Conjugation) is often successful because the unit operations (columns, filters) look similar, even if the chemistry differs. They understand liquid handling at scale.
3. Multi-Boundary Jumps (High Risk): Moving a Small Molecule API expert (Layer 2) to run a Sterile Fill/Finish facility (Layer 4) is a recipe for compliance failure. The operational philosophies are too distinct (Bulk Synthesis vs. Sterile Containment).

---

5. OUTBOUND TRANSFER ANALYSIS – ROLE LEVEL DETAIL

Let us analyze the specific outbound vectors for talent. If you are hiring a leader from a specific layer to manage a broader scope, what are the odds of success?

FROM LAYER 1 (Antibody/Bio)

• ✅ High Success Transition: To Layer 3 (Conjugation).
  
  • The Logic: Bioconjugation relies heavily on Tangential Flow Filtration (TFF) and chromatography to remove free payload and impurities. These are the bread-and-butter skills of a Downstream Processing (DSP) scientist from the antibody world. A Layer 1 DSP lead adapts quickly to Layer 3 because they respect the fragility of the protein. They know that if a pump spins too fast, the protein aggregates. This intuition is the hardest thing to teach a chemist; a biologist brings it for free.
  • The Work-Function: They can immediately audit the flow paths and shear rates in the conjugation suite.
  • The Caveat: They must be trained to respect the “tox.” They cannot simply open a vessel to take a sample as they might in a safe biologics process.
    
• ⚠️ Conditional Transition: To Layer 5 (QC/Analytics).
  • The Logic: A strong Layer 1 technical lead understands the critical quality attributes (CQAs) of the protein (glycosylation, charge variants). However, they may struggle with the complex small-molecule analytical methods required for the payload component (free drug analysis, residual solvents).
  • The Work-Function: They can lead the team effectively provided they have a strong Small Molecule Analytic lieutenant to handle the HPLC/Mass Spec details.
    
• ❌ High-Failure Transition: To Layer 2 (Payload Chemistry).
  • The Logic: Biologics leaders are rarely organic chemists. They do not have the intuition for synthesis pathways, solvent safety, or chemical reactor engineering.
  • The Failure Mode: Placing a Bio-lead in charge of the chemical supply chain invites delay. They will be unable to troubleshoot a synthesis failure or effectively audit a CDMO’s chemical hygiene. They will be “blinded by science” by their subordinates or partners.

FROM LAYER 2 (Linker & Payload/Chem)

• ✅ High Success Transition: To Layer 3 (Conjugation) – With Caveats.
  
  • The Logic: Chemists understand the “reaction” part of conjugation better than anyone. They understand stoichiometry, kinetics, and thermodynamics. They can optimize the reaction conditions to maximize yield.
  • The Risk: They often treat the antibody like a sturdy chemical reagent. They may use mixing speeds or temperatures that denature the protein. If they can learn “protein hygiene” (cold chain, low shear), they become excellent Conjugation leads.
    
• ⚠️ Conditional Transition: To Layer 1 (Antibody).
  • The Logic: Almost never happens successfully in technical roles. A synthetic chemist has no business managing a bioreactor.
  • The Exception: In procurement or supply chain roles, they can be effective due to their rigor. They bring a discipline to raw material management that can benefit the biologics side.
    
• ❌ High-Failure Transition: To Layer 4 (Fill/Finish).
  • The Logic: Synthetic chemistry is often about “cleaning up” a messy reaction through crystallization or columns. Sterile Fill/Finish is about “keeping it clean” from the start.
  • The Failure Mode: The mindset shift from purification to asepsis is profound and often unbridgeable. A chemist sees a particle and thinks “filter it out”; a sterile leader sees a particle and thinks “failure investigation.”

FROM LAYER 3 (Bioconjugation)

• ✅ High Success Transition: To Tech Transfer Lead (Cross-Layer).
  
  • The Logic: Layer 3 natives are the truest “ADC natives.” They have been forced to understand the incoming antibody (L1) and the incoming payload (L2) to make their step work. They have had to negotiate specifications with both upstream teams.
  • The Work-Function: They are naturally positioned to oversee the entire tech transfer process because they understand the interconnectivity of the stack.
    
• ⚠️ Conditional Transition: To Layer 4 (Fill/Finish).
  • The Logic: The formulated bulk drug substance leaving Layer 3 flows directly into Layer 4. A Layer 3 leader understands the formulation buffer and stability profile. They know why the drug precipitates.
  • The Condition: With support on sterility assurance (the regulatory aspect), they can manage the interface well.
    
• ❌ High-Failure Transition: To Pure Discovery.
  • The Logic: Layer 3 manufacturing leaders are process engineers. They are solvers of scale-up problems, not inventors of novel linker chemistries. Their skill is in making the process robust, not in designing the molecule.

FROM LAYER 4 (Fill & Finish)

• ✅ High Success Transition: To Site Head (Operational).
  
  • The Logic: Layer 4 is the bottleneck of revenue. Leaders here are masters of scheduling, logistics, and regulatory compliance (Annex 1). They make excellent Site Heads because they are disciplined operationalists. They run tight ships and understand that a day of downtime is millions in lost opportunity.
    
• ⚠️ Conditional Transition: To Supply Chain VP.
  • The Logic: They feel the pain of every upstream delay. They are highly motivated to fix the supply chain, but may lack the technical nuance to negotiate with CDMOs in Layers 1 and 2 regarding technical deviations. They may push for speed when the science demands caution.
    
• ❌ High-Failure Transition: To Layer 3 (Conjugation).
  • The Logic: They are used to receiving a finished liquid. They rarely have the process science background to troubleshoot a failed conjugation reaction or a clogged TFF filter. They are “finishers,” not “makers.”

FROM LAYER 5 (Characterisation & QC)

• ✅ High Success Transition: To Head of CMC / Regulatory Affairs.
  
  • The Logic: This is the “God View.” The Analytical lead sees the data from every single layer. They know if the antibody was stressed in Layer 1; they know if the free-drug levels rose in Layer 3. Because they hold the “truth” of the molecule, they make exceptional strategic heads of CMC. They can write the story of the drug for the regulators.
    
• ⚠️ Conditional Transition: To Manufacturing Operations.
  • The Logic: They are great at identifying problems, but not always great at fixing them on the plant floor. They risk becoming “compliance cops” rather than “production enablers.” They may shut down a line for a minor deviation that an experienced operator knows is safe.
    
• ❌ High-Failure Transition: To Layer 2 (Chemistry Synthesis).
  • The Logic: Knowing how to measure a molecule is not the same as knowing how to make it. They can analyze the impurity profile, but they cannot redesign the synthesis route to eliminate it.

---

6. HIGH-VALUE INTEGRATOR ARCHETYPES

In my search practice, there are specific profiles that command a massive premium—often 30% to 50% above standard market rates. These are the “Integrators.” They are individuals whose career paths have forced them to span the boundaries of the Y-shaped stack. Finding one of these is like finding a Rosetta Stone for your technical operations.

A) The “Biotic Chemist” (Payload Chemist → Conjugation MSAT)

• The Profile: A PhD organic chemist who spent 5 years in small molecule synthesis (Layer 2) but then moved into a conjugation group (Layer 3) and learned TFF and protein handling.
• The Value: They can talk mechanism with the chemists and stability with the biologists. They are the ultimate troubleshooters for “stalled” reactions. They prevent the finger-pointing that typically occurs when a batch fails because they can assess both the chemical kinetics and the biological stability.
• Recruitment Signal: Look for candidates who did a post-doc in chemical biology after a PhD in total synthesis, or who moved from a “Big Pharma” API group to a mid-sized Biotech ADC group.

B) The “Sterile Architect” (Conjugation MSAT → Fill/Finish Tech Transfer)

• The Profile: An engineer who spent years in Conjugation (Layer 3) optimizing formulation buffers, who then moved to a CDMO focused on Fill/Finish (Layer 4).
• The Value: They bridge the gap between “making the drug” and “putting it in a vial.” They anticipate how upstream process changes (like a buffer switch in Layer 3) will cause precipitation or viscosity issues in the filling needles at Layer 4. They save months of “formulation bridging” studies.
• Recruitment Signal: Look for process engineers who have moved from “Upstream” (in the ADC context, L3) to “Downstream” (L4) roles within the same large organization.

C) The “Data Strategist” (Bioanalytics Director → Head of Global CMC)

• The Profile: A heavy-hitter in mass spectrometry and method validation (Layer 5) who stepped up to manage the overall CMC timeline.
• The Value: They de-risk the program by designing the “control strategy” early. They know exactly what the FDA/EMA will ask for regarding impurity characterisation. They don’t just build a supply chain; they build a defensible regulatory package. They prevent the “Day 60” surprise where regulators reject the comparability strategy.
• Recruitment Signal: Look for analytical leaders who have been the “CMC Lead” for a program filing (IND or BLA), not just the head of a lab.

D) The “Safety Sovereign” (Containment Engineering → ADC Site Head)

• The Profile: An engineer with deep roots in HPAPI containment (isolators, negative pressure) who learns GMP biologics operations.
• The Value: ADCs are dangerous. A Site Head who doesn’t understand containment puts the workforce at risk and invites regulatory shutdowns. This profile ensures the facility is safe (Layer 2 logic) while compliant with sterile standards (Layer 4 logic). They manage the physical intersection of the facility.
• Recruitment Signal: Look for backgrounds in EHS or Engineering in “Highly Potent” facilities before moving into general management.

---

7. NON-TRANSFERABLE ZONES (FAILURE ZONES)

Conversely, we see repeated patterns of failure when organizations force talent into “Non-Transferable Zones.” These are hires that look good on a press release – often big names from big companies – but implode during execution.

The “Small Molecule Generalist” Trap I have seen Boards hire a VP of Manufacturing from a traditional pharma background (tablets/solid dosage) to run an ADC operation. Their resume is impressive—decades of experience, efficiency expert, Six Sigma Black Belt.

• The Failure: They treat the antibody (Layer 1) like a chemical commodity. They push for “lean manufacturing” and inventory reduction in ways that threaten the stability of the biological supply. They try to apply deterministic logic to probabilistic biological processes. They demand “root cause” for yield fluctuations that are simply biological noise. The culture clashes with the scientific staff lead to attrition, and the “lean” initiatives often lead to “starved” processes that fail.

The “Biologics Purist” managing Payload Supply A company promotes their star Antibody Director to oversee the entire external manufacturing network, including the Layer 2 payload CDMOs.

• The Failure: They lack the vocabulary to audit a chemical synthesis facility. When the CDMO says “we have a crystallization issue,” the Biologics Purist nods but doesn’t understand the gravity or the solution. They cannot effectively challenge the CDMO’s technical excuses. They focus on the documentation (which looks fine) rather than the chemistry (which is failing). The payload supply runs late, and the entire Y-chain halts.

The “Sterile DP” Leader in Conjugation Hiring a Fill/Finish expert to run a Bioconjugation facility.

• The Failure: Conjugation is a reaction step; it is chemical synthesis happening on a protein. A Fill/Finish leader is trained to preserve the product, not modify it. They often struggle with the process development aspects of Layer 3—optimizing reaction times, temperatures, and stoichiometries. They focus on the environment (clean rooms, gowning) rather than the science (reaction engineering). They create a facility that is beautifully clean but produces no product.

The “Conventional QC Head” lacking ADC Dual-Discipline Hiring a QC Head from a standard mAb company.

• The Failure: They staff the lab with biologists. When the release testing requires complex HPLC or mass spec analysis of the free drug, the team lacks the skill. They rely on the CDMO’s data without being able to critique it. When an Out-Of-Specification (OOS) result occurs, they cannot determine if it is a real failure or a method artifact. The release is delayed by months of “investigation” that a chemist could have solved in an afternoon.

---

8. CEO, BOARD & INVESTOR IMPLICATIONS

For the target audience of this article – the CEOs and investors capitalizing these ventures – the implications are financial and strategic.

Dependency-Chain Leadership is a Board Issue When evaluating a management team, you cannot simply tick boxes for “Head of CMC” or “VP of Quality.” You must audit the connectivity of their experience. Does the Head of CMC have a “minor” in a second layer? Or are they a siloed specialist? A leadership team composed of five siloed experts will produce five siloed manufacturing steps, but they will fail to produce a coherent ADC. You need at least one “Integrator” at the executive level.

Portfolio Risk is Tied to Talent Architecture We often see investors conduct deep technical due diligence on the linker chemistry or the target antigen. Rarely do they conduct “Organizational Due Diligence” on the interface management.

• The Reality: A mediocre ADC technology run by an integrated, cross-disciplinary leadership team will often beat a superior technology run by siloed leaders. The integrated team will hit the clinic faster and with more reliable supply. A six-month delay in manufacturing can wipe out the value advantage of a slightly better molecule.

Integrators Derisk Platforms Hiring an “Integrator” (as defined in Section 6) is an act of risk mitigation. These individuals are expensive, and they are hard to find. However, the ROI on their compensation is measured in months of cash burn saved. If an Integrator prevents a single failed batch or a single tech-transfer delay, they have paid for their salary ten times over. Do not haggle over the salary of the person who bridges the gap between Layer 2 and Layer 3.

The “Shadow” Org Chart Do not look at the official org chart. Look at the “Shadow” org chart of communication. Who talks to whom? If the Layer 1 team never speaks to the Layer 2 team, and they only meet at the Layer 3 handoff, you have a structural failure waiting to happen. You must force integration through “matrix” structures or “Tech Transfer Tiger Teams” that span the layers.

---

9. FINAL CONCLUSION

The Antibody-Drug Conjugate is one of the most promising modalities in modern medicine, but it is also one of the most unforgiving supply chain challenges. We must stop pretending that standard biotech hiring playbooks apply here.

Success in this space is not about stacking capacity; it is about engineering the flow of information and intuition between disparate scientific tribes. It is about recognizing that the Y-shaped dependency chain requires a new breed of leadership – one that is comfortable in the gray areas between biology and chemistry, between synthesis and sterility.

As you look at your organizational chart, or the chart of the company you are about to invest in, ask yourself if the bridges between layers are manned by people who can speak both languages.

If you can’t map your internal bridges across the dependency chain, you aren’t operating an ADC company – you’re running a collection of siloed science projects hoping integration happens by accident.

Who Are We?

ProGen Search is an Executive Search & Market Intelligence firm. We specialize in VP, C-Suite, and Board-level hiring across the Biotech, CRO, and CDMO sectors. The firm partners with VC-backed startups, PE-owned platforms, and public companies, supporting talent strategy across modalities like ADCs, cell and gene therapy, radiopharmaceuticals, bispecifics, RNA therapeutics, and other emerging modalities. ProGen also works with platform companies in AI-driven drug discovery, synthetic biology, and bioinformatics, delivering on critical roles in CMC, GMP operations, quality, regulatory, clinical, and business development. Byron – the Founder – can be reached here.

Are you hiring in this area?
Looking for support, whether hiring or market intelligence?

Speak to a specialist today, click here – https://calendly.com/byron-fitzgerald-1/adc-leadership-hiring